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We previously reported that an Nkx2-5-GFP bacterial artificial
chromosome in transgenic mice recapitulated the endogenous
gene activity in the heart. Here, we identified three additional
previously uncharacterized distal enhancer modules of Nkx2-5:
UH6, which directed transgene expression in the right ventricle,
interventricular septum, and atrial ventricular canal; UH5, which
directed expression in both atria; and UH4, which directed trans-
gene expression in tongue muscle. Nkx2-5 enhancers drive cardio-
genic gene activity from the earliest progenitors to the late-stage
embryonic heart, reside within its 27 kb of 5 flanking sequences,
organized in a tandem array. Nkx2-5 enhancers involved with
stomach-, tongue-, and chamber-restricted expression displayed
lacZ transgene activity and chromatin histone acetylation patterns
consistent with tissue-specific expression. An examination of
Nkx2-5 gene activity in murine embryonic stem cells converted to
beating embryoid bodies showed that only the proximal active
region 2 and GATA-Smad enhancers were chromatin-remodeled.
Chromatin remodeling of active region 2 and GATA-Smad enhanc-
ers were blunted by noggin coexpression, which indicated depen-
dence on bone morphogenetic protein signaling for their chroma-
tin activation during activation of Nkx2-5 expression.
enhancer modules  heart development  Nkx2-5 gene regulation
Nkx2-5 (1), also called Csx (2), is a vertebrate homologue of thehomeobox tinman gene (3), which is required for cardiac
development in insects and vertebrates (3, 4). Nkx2-5 is expressed
in early cardiac progenitor cells before cardiogenic differentiation
and through adulthood (see ref. 5 for review) and demarcates the
heart field (6). Nkx2-5 also is expressed to pharyngeal endoderm,
spleen, distal stomach, and tongue muscle (1). Heart formation is
dependent on signals from adjacent endoderm (7). Activation of
tinman transcription in dorsal mesoderm is dependent on signaling
by the bone morphogenetic protein (BMP) family member deca-
pentaplegic (8). Schultheiss et al. (9) showed that ectopic applica-
tion of BMPs to regions of chick embryos allowed for the induction
ofNkx2-5. Activin, another TGF- familymember, alsomay induce
cardiogenesis (10), whereas combined BMP2 and FGF4 signaling
may be necessary to induce cardiogenesis in nonprecardiac embry-
onic mesoderm (11). Targeted disruption of Nkx2-5 caused early
embryonic lethality, with cardiac development arrested at the linear
heart-tube stage (12, 13), similar to that seen in BMP2-null mouse
embryos (14).Recent studies showed thatmutations inNkx2-5were
responsible for congenital cardiac malformations and atrioventric-
ular conduction abnormalities in humans (15).
The Nkx2-5 gene has demonstrated surprising complexity, with
multiple enhancers acting in distinct populations of cardiomyocytes
during development (16–19). Schwartz and Olson (20) described a
model for cardiac development based on the modularity of tran-
scriptional units that control Nkx2-5 and suggest a potential role for
this modularity in the evolution of the multichambered heart. Chi
et al. (21) reported that transgenic mice harboring a GFP reporter
gene under the regulation of the murine Nkx2-5 genomic locus in
a bacterial artificial chromosome (BAC) closely resembled the
endogenous Nkx2-5 gene activity. Thus, core cardiac regulatory
regions were apparently circumscribed within this BAC. The
present study revealed that all of the chamber-specific enhancers
are organized in a distal tandem array, consistent with the idea that
the multichambered heart evolved as a modular organ (22) under
the control of individual regulatorymodules (23, 24).Many of these
distal Nkx2-5 enhancer regions displayed cardiac-restricted histone
acetylation patterns indicative of activated chromatin remodeling
(25–27). In addition, among the many regulatory enhancers, only
two enhancers were structurally remodeled by histone acetylation,
which coincided and correlated well with Nkx2-5 gene activation.
Experimental Procedures
BAC Clones. BAC clone RP23-130D16 was obtained from the
BACPAC Resource Center at Children’s Hospital Oakland Re-
search Institute in Oakland, CA (http:bacpac.chori.org). RP23-
130D16 was constructed from C57BL6J mouse DNA in
pBACe3.6 vector, and it contained16 kb of 5 flanking sequences
and 180 kb of 3 flanking sequences of Nkx2-5 confirmed by PCR
and BAC end-sequencing. The bacteria host strain for BAC clones
was DH10B (recA, recBC). Retrofitting the Nkx2-5-GFP-BAC
clone with loxP transposons was performed as described in refs.
28–31. BAC cloning was described by Chi et al. (21) and Muyrers
et al. (32). SJ-1 cells were kindly provided by Bert O’Malley (Baylor
College of Medicine), which was modified from the DY380 Esch-
erichia coli cell line (33) by deleting -galactosidase sequences from
the bacterial genome by homologous recombination, which elimi-
nated recombination between lacZ sequences in the bacterial
genome with the targeting construct. Transgenic lines were main-
tained on C57BL6 background.
Inserting loxP-Tn10 into Nkx2-5 GFP BAC Clone. Retrofitting the
Nkx2-5 GFP BAC clone with loxP transposons was performed in a
manner similar to that described in ref. 29. A newly developed
transposon plasmid, pTnMarkerless1 (31), was used to retrofit
Nkx2-5 GFP BAC.
Construction of Targeting Vectors. The targeting vector was con-
structed on pKO1905 backbone (Stratagene), as described in ref.
21. A 13-kb SalI fragment was cloned into the SalI site of pBlue-
script-SK to generate pBS-Nkx2-5 clone 2. The lacZ cDNA from
pPD46.21 was subcloned in-frame into theXhoI site of pBS-Nkx2-5
clone 2 after modification to generate pBS-Nkx2-5lacZ construct.
A 7-kb fragment containing 3.4 kb of Nkx2-5 sequences upstream
Abbreviations: BAC, bacterial artificial chromosome; BMP, bone morphogenetic protein;
En, embryonic day n; LV, left ventricle; RV, right ventricle; IV, interventricular septum; AVC,
atrioventricular canal: ChIP, chromatin immunoprecipitation; AR, active region.
To whom correspondence should be addressed. E-mail: rschwartz@ibt.tamhsc.edu.
© 2005 by The National Academy of Sciences of the USA
13490–13495  PNAS  September 20, 2005  vol. 102  no. 38 www.pnas.orgcgidoi10.1073pnas.0504295102
of the ATG site and lacZ cDNA from pBS-Nkx2-5lacZ generated
by NotI and XhoI digestion was subcloned into NotI and XhoI sites
of the targeting vector. A genomic clone of Nkx2-5 containing 3
flanking sequences was kindly provided by Katherine Yutzey
(Children’s Hospital, Cincinnati), and a 1.4-kb fragment of 3
flanking sequences generated by BamHI and SmaI digestion was
subcloned into the BamHI and HpaI sites of the targeting vector.
Assay of Enhancers in Transgenic Mice. Different enhancer regions
were cloned into the Hsp68lacZ reporter gene (34). UH4 was
subcloned by PCR using Pfx DNA polymerase (Stratagene) into
ZeroBlunt TOPO vector (Invitrogen). UH6 is a 7.3-kb fragment
from a BamHI library generated from the 112-kb BAC genomic
DNA, and UH5 is a 2.6-kb fragment from a HindIII library
generated from the 112-kb BAC genomic DNA (21). Transgenic
embryos were identified by PCR analysis of yolk-sac DNA by using
a pair of lacZ primers and confirmed by Southern blot analysis. At
least three independent transgenic mouse lines were evaluated for
each lacZ transgene.
Sequence Alignment and Visualization Using VISTA. The genomic
sequences of Nkx2-5(mCG1575) and Csx (hCG41243) were ob-
tained by using theCeleraDiscovery System (www.celera.com)The
112-kb Nkx2-5 BAC sequences from the mouse genome were
aligned against an equivalent portion of the human Csx sequences
by using VISTA software (www-gsd.lbl.govvista) and were used for
comparisons of noncoding regions (35).
ES Cell Culture, Transfection, and Differentiation. AB2.2 ES cells
were routinely grown on gelatinized plates in the presence of
lymphocyte inhibitory factor. pNoggin-CS2 (kindly provided by
Richard Harland, University of California, Berkeley) and pCS2
(kindly provided by Dave Turner, University of Michigan, Ann
Arbor) were transfected into ES cells, respectively, by using the
Effectene transfection reagent kit (Qiagen, Valencia, CA). Embry-
oid bodies were made by using the ‘‘hanging drop’’ method (36)
using ES cells 24 h after transfection.
Chromatin Immunoprecipitation (ChIP) Assay. ChIP assays were per-
formed as described in refs. 37 and 38. ES cell lysates were
precleared by incubation with salmon sperm DNAprotein A
agarose-50% slurry (Santa Cruz Biotechnology), and ChIP was
performed with 10 g of anti-acetylhistone H3 and H4 antibodies
(Santa Cruz Biotechnology). DNA fragments were used for PCR
amplifications with appropriate primers in 25-l reactions contain-
ing 2 l of sample DNA. Thirty cycles of amplification are typically
used. The following primers were used: active region 2 (AR2)
enhancer, 5-CTGCTCATCCATCAGCCAGACGAAGA-3 and
5-GAAAGATAAGCTGCAACTATCACCCGG-3, 357-bp
product; G-S(-6211, -5974) enhancer, 5-CAGTCTTGGGAGCT-
CAAGACTAACC-3 and 5-CAGATCCCCAAGCTTACTAG-
CAACTAC-3, 255-bp product; active region 1 (AR1) enhancer,
5-CTGGGTCCTAATGCGGGTGGCGTCTC-3 and 5-AAC-
CCTCTGCTGTGTGGCCTTGTATCT-3, 246-bp product;
UH6-LV enhancer, 5-CCCCACAGCACAGAAAGTTCA-
GAATCC-3 and 5-CACCCACCAAAACACAGCCCCAG-
GATAA-3, 299-bp product; UH5-atria enhancer, 5-CCCTGC-
TATTGAGGATGCTCTCTTATG-3 and 5-TGGCAAAG-
CAAGCAGAGCAGAGGGAGGA-3, 274-bp product; and
tongue enhancer, 5-CCCTATCTAACCAGCCATCAGTGAG-3
and 5-CGGCCTCCCTGCTTCCTGTAC-3, 248-bp product. The
PCR products were analyzed on 2% agarose gels.
RNA Isolation and RT-PCR Analysis. Total RNAwas isolated fromES
cells or embryoid bodies by using TRIzol reagents (Invitrogen).
Reverse transcription was performed by using the SuperScript III
first-strand synthesis system (Invitrogen) according to the manu-
facturer’s protocol. Each reaction contained 200 ng of total RNA.
PCR was performed by using Taq DNA polymerase (Invitrogen)
with 25 cycles of amplification. Relative quantities between samples
were normalized to GAPDH levels. The primers used for Nkx2-5
were 5-TCTCCGATCCATCCCACTTTATTG-3 and 5-
TTGCGTTACGCACTCACTTTAATG-3, 222-bp product.
Fig. 1. Generation of nested deletions of Nkx2-5-GFP BAC identified the most
distal 5 border of the cardiac regulatory locus. (A) A green fluorescent image
merged with a brightfield image of the Nkx2-5-GFP-BAC mouse embryo. (B) The
strategy as a schematic diagram for generating gap deletions by retrofitting a
loxP site by transposition into the Nkx2-5-GFP-BAC. Deletions were generated by
Cre recombinase between the endogenous loxP site in the BAC vector and the
transposed loxP site. (C) The expression pattern of e-Nkx2-5GFP-BAC transgenic
mouse line. Shown are brightfield (a), green fluorescent (b), and merged (c)
images of the left ventral view and the brightfield (d) green fluorescent (e), and
merged (f) images of the right ventral view of an e-Nkx2-5-GFP-BAC transgenic
embryo at E11.5, showing GFP expression in the left atrium (LA) and left ventricle
(LV). (D) The series of gap deletion constructs run in a pulsed-field gel electro-
phoresis. The e-Nkx2-5-GFP-BAC construct (which has 27 kb on the 5 flanking
sequencesand60kbonthe3flankingsequences)wasselectedformicroinjection
to make transgenic mouse lines. (E) A schematic diagram of Nkx2-5-LacZ-BAC
construct, which has 16 kb on the 5 flanking sequences and 180 kb on the 3
flankingsequences.LacZexpressionwasobservedinNkx2-5-LacZ-BACmice inthe
right ventricle (RV) and LV but was absent in both atria. LacZ expression also was
observed in the distal stomach region. RA, right atrium.
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Results
Generation of Nested Deletions of Nkx2-5-GFP-BAC Identified the
Most Distal 5 Border of the Cardiac Regulatory Locus. As shown in
Fig. 1A and by Chi et al. (21), a BAC clone that contained 55 kb
of both 5 and 3 sequences flanking the Nkx2-5 coding region was
capable of recapitulating the endogenous gene activity in the heart.
We used Tn10 random insertion mutagenesis to generate progres-
sive deletions from one end in the BAC clone by CreloxP
recombination in E. coli (Fig. 1B). This highly efficient method
generated end deletions in the modified BAC clone and obviated
the need to modify a number of overlapping BACs (39). A nested
deletion series was generated in theNkx2-5-GFP-BAC construct by
random insertion of retrofited loxP sites. The deletion clone
e-Nkx2-5-GFP-BAC was selected for microinjection, and all three
transgenic founder mouse lines showed expression patterns similar
to that of the full-length Nkx2-5-GFP-BAC line. GFP expression
was observed in four chambers of the heart (Fig. 1C), in the pyloric
sphincter, and in the spleen (not shown). GFP fluorescence was not
observed in the tongue muscle. It is important to note that the 5
flanking sequences in the serial deletions ranged from 38 kb to
15 kb (Fig. 1D), and the 3 flanking sequences remained constant.
The size of the clones in the deletion series is random, and
transposition itself had no bias to any particular regions in Nkx2-
5-GFP-BAC. We obtained two lines of Nkx2-5LacZ-BAC trans-
genic mice, and both lines have the same expression pattern as that
shown with the 14-kb upstream region of Nkx2-5. LacZ expression
was observed in the entire right ventricle (RV) and the trabeculated
layer of the left ventricle (LV) but was missing from the compact
layer of the LV and from both atria (Fig. 1E). Apparently, there
were no additional regulatory elements in the extensive 3 flanking
regions that extended Nkx2-5 gene expression.
VISTA Revealed Multiple Noncoding Regions Containing High Levels of
Cross-Species Homology. Comparison of genomic sequences for
conserved noncoding sequences has proved fruitful for detecting
conserved regulatory regions. Long-range genomic sequence align-
ment between mouse (Nkx2-5) and human (Csx) demonstrated
multiple peaks of high levels of homology (Fig. 2), a subset of which
corresponded precisely with known Nkx2-5 enhancers and coding
regions. DH1 matched to a RV enhancer (16). UH7 overlapped
AR2, a proximal enhancer region responsive to BMP-Smad sig-
naling (41, 42) that directed transgene expression in the cardiac
crescent and later in the RV, stomach, and thyroid (17–20). The
proximal peak of UH6 corresponded to another RV enhancer
driven by GATA4 (19).
Transgenic Analysis of the Conserved Noncoding Regions Revealed
Previously Uncharacterized Enhancers. The ability of each of these
highly homologous regions, UH4, UH5, and UH6, to drive lacZ
expression was tested in transgenic mice by using the Hsp68LacZ
expression vector. UH6-Hsp68LacZ directed lacZ expression at
embryonic (E) days 10.5 and 12.5 in the entire RV and the
interventricular septum (IVS) (Fig. 3 Aa–Af). LacZ staining also
was observed in the trabecular layer of the LV (Fig. 3 Ab, Ae, and
Af), indicating that there was a weak LV enhancer within this
transgene, in addition to the known RV enhancer within the UH6
region. In the atrial region, there was a subset of LacZ-positive cells
in the interatrial groove. There also was a cluster of LacZ-positive
cells in the IVS. The pattern of LacZ expression remained constant
until E12.5 (Fig. 3 Ac–Af) and later (data not shown).
The UH5-Hsp68lacZ transgene directed LacZ expression
throughout the looping heart at E9.5 (Fig. 3Ba), in the common
atria, the common ventricle, and the aortic sac (Fig. 3Bb). LacZ
expression also was observed in the foregut at E9.5 (Fig. 3Ba). By
E12.5, the LacZ expression was restricted to both atria, AVC, IVS,
and a subset of cardiomyocytes in the LV but was absent from the
RV (Fig. 3 Bc–Bg). LacZ expression also was observed at E12.5 in
the distal stomach region (Fig. 3Bd, black arrow), which is the site
of foregut-derived pyloric sphincter and the spleen, that express
Nkx2-5. In situ hybridization using antisense BMP2 probe showed
that BMP2 gene was expressed in the myocardial layers overlaying
the AVC (Fig. 3C), which colocalized with the LacZ expression
pattern of both UH5 and UH6-Hsp68lacZ in the AVC.
Identification of the Tongue Enhancer and texas. UH4-HSP68LacZ
transgene was expressed specifically in the tongue primordia at
E11.5 (Fig. 4 a and b) and strongly in the tongue muscle at E12.5
(Fig. 4 c and d) and after (Fig. 4 e–h), whereas weaker expression
was noted in the somites and body wall muscle (Fig. 4f). Surpris-
ingly, tongue muscle expression was not observed in either the
Fig. 2. Pairwise alignment of the mouse
and human Nkx2-5Csx loci revealed mul-
tiple upstream noncoding regions of high
homology. Conserved sequences are
shown relative to their position in the
mouse (horizontal axes), and their percent
cross-homology between mouse and hu-
man sequences (50–100%) are indicated
on the vertical axes. The location of the
gene texas is indicated by double under-
lines. Horizontal arrows indicate the direc-
tion of transcription for each gene. Peaks
representing the noncoding sequences
(red) fitting the criteria for conserved ele-
ments as well as coding sequences (blue)
meeting the percentage criteria over their
entire length are indicated. UH, upstream
homology region. The arrow indicates the
end of the eNkx2-5-GFP deletion construct
on the 5 flanking region. UH4, UH5, and
UH6 above the profile indicate the location
of the fragments for transgenic analysis.
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Nkx2-5-GFP-BAC transgenic mice or the transgenic mice gener-
ated from the genomic region encompassing 22.7 kb surrounding
theNkx2-5 gene. Complicating matters is the fact that the first peak
of UH2 (arrow in Fig. 2) corresponds precisely to exon 1 of an EST
from a differentiated C2C12 myotube library (GenBank accession
no. AA597013; IMAGE clone ID, 1059294 5), and the EST
contains two other exons with 100% homology to the more
upstream genomic sequences (12480–12622 and 263–407) in the
BAC. The corresponding gene lies on the 5 side of Nkx2-5 and is
transcribed in the opposite orientation and was named texas for the
5-terminal-expressed NKX2-5-associated skeletal muscle gene.
Histone Acetylation Pattern on Nkx2-5 Enhancers CorrelatedWell with
Their Activation both Temporally and Spatially. Histone acetylation
increases the accessibility of nucleosomal DNA to sequence-
specific DNA-binding proteins and is associated with transcrip-
tional activation (25, 26). Fig. 5 shows a schematic diagram of the
enhancers analyzed by aChIP assay (27, 37, 38) with anti-acetylated
histone H4 antibodies. Liver tissues do not express Nkx2-5 and
served as negative controls. Three primary conclusions were drawn
from this analysis (Fig. 5A). First, histone acetylation patterns
showed tissue specificity: cardiac enhancers as indicated by the
detection of AR2, G-S, AR1, UH6-LV, and UH5-atria, and UH4-
tongue PCR-amplifiedDNA fragments were retrieved from aChIP
assay with anti-acetylated histone H4 antibodies from E12.5 and
neonatal hearts. Enhancers that direct expression in the stomach
and spleen, AR2 and AR1 sequences, were immunoprecipitated
with anti-acetylhistone H4 antibodies from E12.5 neonatal stom-
ach. The tongue enhancer (UH4) was immunoprecipitated only
fromE12.5 and neonatal tongue tissues and not from cardiac tissue.
Second, the anti-acetylhistone H4 ChIP pattern correlated well
with the activation of these enhancers, as determined by transgenic
analysis (Figs. 3 and 4). In addition, antibodies directed to acetyl-
histone H3 and anti-acetylhistone H4 had similar superimposable
ChIP patterns on these different Nkx2-5 enhancers (data not
shown).
Which of these modular enhancers were activated during the
earliest appearance of theNkx2-5 gene activity? As shown in Fig.
5, Nkx2-5 started to be expressed on day 6 in embryoid bodies
when embryoid bodies were used as an in vitro system to mimic
cardiac differentiation (36) until day 8. Noggin expression in
embryoid bodies, which blocks BMP signaling (43), significantly
diminished the earliest Nkx2-5 induction (Fig. 5B). Third, only
two cardiac enhancers, AR2 and G-S, were PCR-amplified from
ChIP from embryoid bodies at days 6 and 8 transfected with the
control plasmid pCS2 yet were not immunoprecipitated from
embryoid bodies transfected with noggin at the same time points
(Fig. 5C). None of the other Nkx2-5 enhancers assayed here,
AR1, UH6-LV, UH5-atria, and UH4-tongue, were immunopre-
cipitated with anti-acetylhistone H4 antibodies at the same time
points in embryoid bodies. In addition, Fig. 5D shows a whole-
mount X-gal staining of an E7.5 embryo carrying the G-S-
Hsp68lacZ transgene in the early cardiac crescent, consistent
with our previous observations (44) that the GATA-Smad-
enriched enhancer is activated early in cardiogenesis.
Discussion
Organization of Nkx2-5 Enhancers: Proximal vs. Distal Enhancers.
Schwartz and Olson (20) described a model for cardiac develop-
ment based on the modular nature of transcriptional units that
Fig. 3. Transgenic analysis of the con-
served noncoding regions functioned as
previously uncharacterized enhancers for
expression in the interventricular septum
(IVS), atrial ventricular canal, and atria in
mouse embryos. (A) Whole-mount X-gal
staining (a) and transverse sections (b) of
an E10.5 embryo carrying the UH6-
Hsp68lacZ transgene are shown. LacZ ex-
pression was observed uniformly in the
entire RV and in a subset of cells in the
trabecular layer and septal wall of the LV.
There was a cluster of LacZ-positive myo-
cardial cells in the IVS and in the atrio-
ventricular canal (AVC). (c and d) Whole-
mount X-gal staining (c) and transverse
sections (d) of an E12.5 embryo carrying
the UH6-Hsp68lacZ transgene are shown.
Transgene expression was similar as that
in E10.5. (B) Whole-mount X-gal staining
(a) and transverse sections (b) of an E9.5
embryo carrying the UH5-Hsp68lacZ
transgene, in which the LacZ expression is
homogenous in the looping heart at E9.5.
LacZ also is expressed in the foregut at
this stage (as indicated by an arrow in a).
Bb shows the transverse section of the
embryo in a stained with nuclear fast red,
revealing LacZ expression in the aortic
sac, the common atria, and the common
ventricle. Bc (right ventral view) and Bd
(left ventral view) show the whole-mount
staining at E12.5, with LacZ expression
restricted to the RA and LA, AVC, IVS, and
a subset of cells in the LV, also in the distal
stomach region (as indicated by an arrow
in d). Be–Bg show the transverse sections
of the embryo in c. (C) In situ hybridiza-
tion using antisense Bmp-2 mRNA on E11.5 embryonic heart, showing the intense staining in the myocardial layer of the AVC. Ca is the whole-heart view,
and Cb is a heart cut in the AVC region and viewed from the above.
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control Nkx2-5 expression at a time when the LV and atrial
enhancers remained unidentified. Three additional previously un-
characterized enhancer regions of Nkx2-5 were identified, and
LacZ expression patterns observed in the heart strongly supported
the ‘‘modular and combinatorial genetic pathway hypothesis’’ for
the formation of vertebrate heart. In addition, congenital cardiac
malformations associated with human Nkx2-5 mutations suggest a
role for Nkx2-5 at later stages of cardiogenesis. Chien and col-
leagues (45) recently reported that a ventricular-restricted knock-
out of Nkx2-5 results in massive trabecular muscle overgrowth and
conduction system defects and suggested that a dysregulation of the
Nkx2-5-BMP-10 axis was responsible for the defects. These findings
indicated that besides the critical role for Nkx2-5 in early cardiac
specification and commitment, it was being used again in later
elaboration of the chambers, septation, and the conduction system.
Possibly, the dosage of Nkx2-5 is tightly regulated in different
chambersregions of the heart by each of the enhancer modules to
achieve its physiological functions.
Interestingly, UH4 corresponded to a highly conserved enhancer
that drove LacZ expression strongly in the tongue muscle. The
finding was especially intriguing because tongue muscle expression
was not observed in either the Nkx2-5 GFP BAC transgenic mice
or the transgenic mice generated from the genomic region encom-
passing 22.7 kb surrounding the Nkx2-5 gene. This observation
suggests that there are strong repressor regions residing around
UH4 and that additional activating regions must reside outside the
BAC for expression in tonguemuscle.We speculate that the tongue
enhancerwas used primarily to drive texas in the tongue and skeletal
muscle but also served as an Nkx2-5 enhancer in the tongue; such
as the intragenic or shared enhancers for muscle-specific transcrip-
tion factors Myf5 and Mrf4 (39).
Histone Acetylation Plays a Role in Establishing Long-Range Transac-
tivation of Nkx2-5 on the Enhancers. We showed that the histone
acetylation patterns of the recently identified Nkx2-5 enhancers
were developmentally regulated and tissue-specific. Histone acet-
ylation patterns correlated well with spatial and temporal activation
of these enhancer elements on the chromosome and in agreement
with the transgenic study; thus, histone acetylation played a role in
regulatingNkx2-5 expression by modulating the activation status of
its enhancers. We also showed that AR2 and G-S enhancers were
chromatin remodeling-dependent on BMP-Smads signaling. This
observation also was in agreement with previous studies showing
that both AR2 and G-S enhancers are essential for Nkx2-5 expres-
sion in the cardiac crescent (41, 42, 44). A single Smad site in AR2
and a cluster of Smads sites in G-S enhancers were required for
enhancer activity at early stages of heart development in vivo. In
fact, deletion of the G-S enhancer, which contains multiple arrays
of Smad andGATADNA-binding sites, blocked the appearance of
reporter gene activity in the cardiac crescent (44). Point mutations
of GATA and Smad sequences in AR2 also blocked expression
during cardiogenesis (41, 42). Also, the multimeric G-S enhancer
activated early in the cardiac crescent was later down-regulated in
E11 transgenic mice (44) and showed a loss of acetylated histones
by E12.5 (Fig. 5), perhaps through enhanced BMP-induced inhib-
itory Smad6 expression (46). In addition, Lassar and colleagues (47)
Fig. 4. Identification of the tongue enhancer identified by UH4-Hsp68lacZ
transgene expression patterns. Whole-mount X-gal staining (a, c, and e–g)
and transverse sections (b, d, and h) of embryos carrying the UH4-
Hsp68lacZNkx2-5 transgene. Transgene expression was observed specifically
in the tongue primordia at E11.5 (a and b) and in the tongue muscle at E12.5
(c and d) and after (e–h). LacZ staining also was seen after E12.5 in the somites
( f, small arrow) and the muscle in the limb ( f, arrowhead).
Fig. 5. Histone H4 acetylation patterns correlated well with temporal and spatial activity of Nkx2-5 distal enhancers and the activation of the proximal AR2
and G-S modules during ES cell induced cardiogenesis. (A) The anti-acetylhistone H4 pattern of Nkx2-5 enhancers from embryonic and neonatal tissues. (B) The
RT-PCR analysis of ES cells and embryoid bodies at different time points after aggregation, with and without noggin. (C) The histone H4 acetylation pattern of
AB2.2 ES cells and embryoid bodies at days 6 and 8 of differentiation. pNoggin-CS2 expression plasmid was transfected into ES cells to block BMP signaling.
pCS2 vector served as a transfection control. (D) Whole-mount X-gal staining of an E7.5 embryo carrying the G-SHsp68lacZ transgene and a schematic diagram
of the enhancers assayed by ChIP for histone acetylation patterns.
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identified three cardiac-activating regions that surround the chick
Nkx2.5 gene, similar to its murine counterpart AR2 (17, 18, 20),
capable of driving transgene expression in the cardiac crescent in a
BMP-responsive fashion and dependent on GATA- and SMAD-
binding sites.
A Model for Nkx2-5 Transcriptional Regulation. We showed that the
earliestNkx2-5 cardiac enhancers wereAR2 andG-S, both of which
are BMP-dependent and proximal to the promoter region. The
previously uncharacterized distal enhancer regions identified in this
study were responsible for chamber-tissue-specific expression of
Nkx2-5 at later stages of cardiogenesis, such as the UH5 enhancer,
which may be regulated by Bmp24, as a signal from the myocar-
dium directly mediating atrioventricular septation (48). The model
proposed here is one ofNkx2-5 being a tightly regulated gene, with
its regulation having two stages that coincide with its functions (Fig.
6): (i) during early cardiac commitment and specification, there
were at least two cardiac enhancers that ensured its uniform
expression in the cardiac crescent; (ii) multiple tandem arrayed
enhancers were then activated during chamber specification, and
these distal enhancers restrict their domains of influence to differ-
ent regionschambers of the heart. This observation was similar to
a cGATA6 enhancer that is activated early and then selectively
marked the atrioventricular conduction system (49). This report on
the chamber-region-specific enhancer analysis of Nkx2-5 strongly
supported the modular and combinatorial genetic pathway hypoth-
esis for the formation of vertebrate heart.
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Fig. 6. A general model for murine embryonic Nkx2-5 transcriptional reg-
ulation.Nkx2-5 is driven by two groups of enhancers: proximal and distal, both
of which are downstream of the BMP-Smad signaling pathway. Earlier on, at
the cardiac crescent stages, secreted BMPs from pharyngeal endoderm stim-
ulate Nkx2-5 gene transcription by chromatin remodeling of the proximal
enhancers G-S and AR2 in the cardiac crescent (CC) and are required for cardiac
commitment and specification. The G-S enhancer is not active in later stages
of heart formation, whereas AR2 provides RV expression. Later, during cham-
ber specification, enriched BMP-Smad signaling may activate the distal en-
hancers, UH5 and UH6, that directNkx2-5 gene activity in the atria, ventricles,
IVS, and AVC during chamberization.
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